ZGNXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States...

Stats
本日の出来高	11.25M
平均出来高	3.10M
時価総額	0.00
EPS	$-0.980 ( 2022-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.56
ATR14	$0.603 (2.26%)

Insider Trading

Date	Person	Action	Amount	type
2022-03-07	Breitmeyer James B	Sell	1 250	Common Stock
2022-03-07	Breitmeyer James B	Sell	9 375	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	6 250	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	9 000	Stock Option (Right to Buy)
2022-03-07	Breitmeyer James B	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 100 transactions
Buy: 446 833 \| Sell: 2 096 567

ボリューム相関

長: 0.49 (neutral)

短: 0.91 (very strong)

Signal:(77.726) Expect same movement, but be aware

Zogenix Inc 相関

10 最も正の相関
BRACU	0.97
ATRS	0.969
ATCX	0.967
XLRN	0.957
CTSO	0.955
EYEN	0.952
ARAY	0.947
NVCN	0.946
ALGN	0.945
FOCS	0.945

10 最も負の相関
NAKD	-0.948
TRIT	-0.935
AHPI	-0.931
AMRB	-0.922
GRPH	-0.922
GRIN	-0.909
PROC	-0.907
CHKEL	-0.905
TUEM	-0.904
LAWS	-0.902

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Zogenix Inc 相関 - 通貨/商品

0.16
( neutral )

0.68
( moderate )

0.64
( weak )

0.40
( neutral )

0.58
( weak )

-0.18
( neutral )

Zogenix Inc 財務諸表

Annual	2021
収益:	$81.69M
総利益:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2021
収益:	$81.69M
総利益:	$76.86M (94.08 %)
EPS:	$-4.24

FY	2020
収益:	$13.64M
総利益:	$13.10M (96.03 %)
EPS:	$-3.90

FY	2019
収益:	$3.65M
総利益:	$3.65M (100.00 %)
EPS:	$-9.74

Financial Reports:

No articles found.

Zogenix Inc

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.